Current position in this corpus
Long-read WGS is not uniformly better for every task, but it is consistently better where read length, phasing, or native-molecule information matters.
Where long reads clearly help
- insertions larger than roughly 10 bp
- structural variants in repetitive regions
- hard medically relevant genes and sequencing dead zones
- breakpoint-level interpretation of complex rearrangements
- phasing of compound events
- native methylation-aware diagnostics
Where short reads remain competitive
- many SNVs outside repetitive regions
- many deletions in nonrepetitive regions
- cost-efficient high-throughput cohort sequencing
- mature tooling and established clinical workflows
Supporting sources
Main tension
- One view in the corpus favors targeted deployment where long reads have the highest incremental value.
- Another view favors a unified long-read clinical platform that replaces multiple follow-up assays.
Open questions
- At what cost and coverage point does long-read WGS become the default rather than the escalation path?
- How much of the remaining short-read advantage is technical, and how much is simply ecosystem maturity?